ReviewWorld journal of gastroenterology2019
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed.
- Review
- Fibrosis-4 index utility for screening liver fibrosis and its association with degenerative complications in patients with type 2 diabetes mellitus: a monocentric study.Medicine and pharmacy reports · 2026Article
- Magnetic Resonance Imaging Systematically Differs from Histology in Quantifying Macrovesicular Liver Steatosis in Individuals with Morbid Obesity: A Prospective Paired MRI-Histology Study in Bariatric Surgery.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Noninvasive liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2026Review
- Quantifying non-alcoholic fatty liver: liver-spleen CT ratio and fat concentration in dual-energy spectral CT : Accuracy comparison with proton density fat fraction MRI.Radiologie (Heidelberg, Germany) · 2026Article
- Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan.World journal of gastroenterology · 2026Review
- Cytokeratin-18 increase as a signal for early liver cell changes in high-fat diet-induced obesity before overt steatohepatitis.Frontiers in endocrinology · 2026Article
- The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional study.Frontiers in nutrition · 2026Article
- The Effect of Short-Term and High-Intensity Functional Circuit Training on Plasma Lipidome Profiles of People Living with and Without HIV.Metabolites · 2025Article
- NUP85 siRNA loaded red blood cell-derived extracellular vesicles alleviate hepatic steatosis in MASLD.Journal of nanobiotechnology · 2025Article
- Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- The relationship between lipid accumulation products and non-alcoholic fatty liver disease among adults in the North of Iran: a cross-sectional study.BMC gastroenterology · 2025Article
- Non-invasive liver fibrosis scores and mortality in a cohort of World Trade Center rescue/recovery workers.BMJ open gastroenterology · 2025Article
- Low-Abundance Proteomics Reveal Pleiotrophin and Fibroblast Growth Factor-21 as Biomarkers of Metabolic Dysfunction-Associated Steatohepatitis.International journal of molecular sciences · 2025Article
- Review
- Screening for metabolic-associated fatty liver disease in type 2 diabetes patients using non-invasive scores and ultrasound: a cross-sectional study in Egypt.BMC gastroenterology · 2025Article
- Article
- FF Swin-Unet: a strategy for automated segmentation and severity scoring of NAFLD.BMC medical imaging · 2025Article
- Predictive effect and clinical diagnosis significance of exosome-related genes for nonalcoholic fatty liver disease-related hepatocellular carcinoma.Scientific reports · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults worldwide. The spectrum of NAFLD ranges from simple steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). NAFLD, especially NASH, may progress to fibrosis, leading to cirrhosis and hepatocellular carcinoma. NAFLD can impose a severe economic burden, and patients with NAFLD-related terminal or deteriorative liver diseases have become one of the main groups receiving liver transplantation. The increasing prevalence of NAFLD and the severe outcomes of NASH make it necessary to use effective methods to identify NAFLD. Although recognized as the gold standard, biopsy is limited by its sampling bias, poor acceptability, and severe complications, such as mortality, bleeding, and pain. Therefore, noninvasive methods are urgently needed to avoid biopsy for diagnosing NAFLD. This review discusses the current noninvasive methods for assessing NAFLD, including steatosis, NASH, and NAFLD-related fibrosis, and explores the advantages and disadvantages of measurement tools. In addition, we analyze potential noninvasive biomarkers for tracking disease processes and monitoring treatment effects, and explore effective algorithms consisting of imaging and nonimaging biomarkers for diagnosing advanced fibrosis and reducing unnecessary biopsies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.